AlphaHelix Molecular Diagnostics AB (4MB) Stock Statistics & Valuation Metrics

AlphaHelix Molecular Diagnostics AB has a market cap or net worth of €1.53M. The enterprise value is ―.

AlphaHelix Molecular Diagnostics AB has 63,398,903 shares outstanding. The number of shares has decreased by -2.65% in one year.

AlphaHelix Molecular Diagnostics AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of AlphaHelix Molecular Diagnostics AB is 2.2. AlphaHelix Molecular Diagnostics AB’s PEG ratio is ―.

In the last 12 months, AlphaHelix Molecular Diagnostics AB had revenue of ― and earned 5.16M in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

AlphaHelix Molecular Diagnostics AB pays an annual dividend of ―, resulting in a dividend yield of ―

AlphaHelix Molecular Diagnostics AB upcoming earnings date is ―, ―.

AlphaHelix Molecular Diagnostics AB as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, AlphaHelix Molecular Diagnostics AB has paid ― in taxes.

AlphaHelix Molecular Diagnostics AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

AlphaHelix Molecular Diagnostics AB has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for AlphaHelix Molecular Diagnostics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―